DYN submits Biologics License Application for z-rostudirsen, seeking Priority Review to shorten FDA approval timeline to six months.
Dyne Therapeutics (NASDAQ:DYN) submitted its Biologics License Application to the FDA for z-rostudirsen, a treatment for Duchenne muscular dystrophy. The company is pursuing Priority Review designation, which could reduce the standard 10-month approval process to six months.
Bernstein recently raised DYN’s price target from $23 to $24, reflecting a nearly 29% upside potential. The stock has risen 11% year-to-date, outperforming broader indices and the pharma sector. The biotech segment has seen strong performance, with smaller firms gaining traction amid favorable FDA leadership changes.
Management aims for a commercial launch in the first quarter of 2027, positioning DYN as a high-growth candidate in the healthcare sector. Analysts anticipate increased M&A and IPO activity in the industry.